Association between imaging surveillance frequency and outcomes following surgical treatment of early-stage lung cancer. (29th November 2022)
- Record Type:
- Journal Article
- Title:
- Association between imaging surveillance frequency and outcomes following surgical treatment of early-stage lung cancer. (29th November 2022)
- Main Title:
- Association between imaging surveillance frequency and outcomes following surgical treatment of early-stage lung cancer
- Authors:
- Heiden, Brendan T
Eaton, Daniel B
Chang, Su-Hsin
Yan, Yan
Schoen, Martin W
Thomas, Theodore S
Patel, Mayank R
Kreisel, Daniel
Nava, Ruben G
Meyers, Bryan F
Kozower, Benjamin D
Puri, Varun - Abstract:
- Abstract: Background: Recent studies have suggested that more frequent postoperative surveillance imaging via computed tomography following lung cancer resection may not improve outcomes. We sought to validate these findings using a uniquely compiled dataset from the Veterans Health Administration, the largest integrated health-care system in the United States. Methods: We performed a retrospective cohort study of veterans with pathologic stage I non-small cell lung cancer receiving surgery (2006-2016). We assessed the relationship between surveillance frequency (chest computed tomography scans within 2 years after surgery) and recurrence-free survival and overall survival. Results: Among 6171 patients, 3047 (49.4%) and 3124 (50.6%) underwent low-frequency (<2 scans per year; every 6-12 months) and high-frequency (≥2 scans per year; every 3-6 months) surveillance, respectively. Factors associated with high-frequency surveillance included being a former smoker (vs current; adjusted odds ratio [aOR] = 1.18, 95% confidence interval [CI] = 1.05 to 1.33), receiving a wedge resection (vs lobectomy; aOR = 1.21, 95% CI = 1.05 to 1.39), and having follow-up with an oncologist (aOR = 1.58, 95% CI = 1.42 to 1.77), whereas African American race was associated with low-frequency surveillance (vs White race; aOR = 0.64, 95% CI = 0.54 to 0.75). With a median (interquartile range) follow-up of 7.3 (3.4-12.5) years, recurrence was detected in 1360 (22.0%) patients. High-frequencyAbstract: Background: Recent studies have suggested that more frequent postoperative surveillance imaging via computed tomography following lung cancer resection may not improve outcomes. We sought to validate these findings using a uniquely compiled dataset from the Veterans Health Administration, the largest integrated health-care system in the United States. Methods: We performed a retrospective cohort study of veterans with pathologic stage I non-small cell lung cancer receiving surgery (2006-2016). We assessed the relationship between surveillance frequency (chest computed tomography scans within 2 years after surgery) and recurrence-free survival and overall survival. Results: Among 6171 patients, 3047 (49.4%) and 3124 (50.6%) underwent low-frequency (<2 scans per year; every 6-12 months) and high-frequency (≥2 scans per year; every 3-6 months) surveillance, respectively. Factors associated with high-frequency surveillance included being a former smoker (vs current; adjusted odds ratio [aOR] = 1.18, 95% confidence interval [CI] = 1.05 to 1.33), receiving a wedge resection (vs lobectomy; aOR = 1.21, 95% CI = 1.05 to 1.39), and having follow-up with an oncologist (aOR = 1.58, 95% CI = 1.42 to 1.77), whereas African American race was associated with low-frequency surveillance (vs White race; aOR = 0.64, 95% CI = 0.54 to 0.75). With a median (interquartile range) follow-up of 7.3 (3.4-12.5) years, recurrence was detected in 1360 (22.0%) patients. High-frequency surveillance was not associated with longer recurrence-free survival (adjusted hazard ratio = 0.93, 95% CI = 0.83 to 1.04, P = .22) or overall survival (adjusted hazard ratio = 1.04, 95% CI = 0.96 to 1.12, P = .35). Conclusions: We found that high-frequency surveillance does not improve outcomes in surgically treated stage I non-small cell lung cancer. Future lung cancer treatment guidelines should consider less frequent surveillance imaging in patients with stage I disease. … (more)
- Is Part Of:
- Journal of the National Cancer Institute. Volume 115:Number 3(2023)
- Journal:
- Journal of the National Cancer Institute
- Issue:
- Volume 115:Number 3(2023)
- Issue Display:
- Volume 115, Issue 3 (2023)
- Year:
- 2023
- Volume:
- 115
- Issue:
- 3
- Issue Sort Value:
- 2023-0115-0003-0000
- Page Start:
- 303
- Page End:
- 310
- Publication Date:
- 2022-11-29
- Subjects:
- Cancer -- Periodicals
Cancer -- Research -- Periodicals
616.994 - Journal URLs:
- https://jnci.oxfordjournals.org/ ↗
http://ukcatalogue.oup.com/ ↗ - DOI:
- 10.1093/jnci/djac208 ↗
- Languages:
- English
- ISSNs:
- 0027-8874
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4830.000000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 26142.xml